Nanobiotix S.A annual free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Nanobiotix S.A Free Cash Flow (FCF) History (NBTX)
Nanobiotix S.A reported −€34.0M in free cash flow for fiscal 2025, a decrease of €13.6M from the previous fiscal year, with a free cash flow margin of −104.19%.
View full Nanobiotix S.A company overviewNanobiotix S.A free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −€34.0M | −€13.6M | — | −104.19% |
| 2024 | 2024-12-31 | −€20.4M | −€7.6M | — | — |
| 2023 | 2023-12-31 | −€12.8M | €24.4M | — | −35.36% |
| 2022 | 2022-12-31 | −€37.2M | −€7.1M | — | −778.79% |
| 2021 | 2021-12-31 | −€30.1M | −€2.5M | — | −1137.14% |
| 2020 | 2020-12-31 | −€27.6M | €14.6M | — | −1100.08% |
| 2019 | 2019-12-31 | −€42.3M | −€15.9M | — | −1663.12% |
| 2018 | 2019-01-01 | −€26.4M | — | — | −758.87% |
Nanobiotix S.A quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Nanobiotix S.A free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −€27.6M to −€34.0M, a net decrease of €6.3M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Nanobiotix S.A filings at SEC.gov ↗